FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891903398> ?p ?o ?g. }

• W2891903398 endingPage "1335" @default.
• W2891903398 startingPage "1326" @default.
• W2891903398 abstract "Objective Combination treatments for patients with rheumatoid arthritis ( RA ) with an inadequate response to methotrexate ( MTX ) alone include the addition of a tumor necrosis factor inhibitor ( TNF i) or the addition of sulfasalazine ( SSZ ) and hydroxychloroquine to MTX (triple therapy). We compared persistence and adherence rates between these 2 combination therapies in US veterans and report the reasons for discontinuation of combination treatment in these groups. Methods Using Veteran's Affairs clinical and administrative data from 2006 to 2012, veterans with RA escalating treatment from MTX to MTX ‐ TNF i or triple therapy were examined for a 12‐month period after combination initiation. Persistence was defined as treatment without a ≥90‐day gap in therapy. Adherence was calculated using the proportion of days covered ≥80% at 12 months. Matching weights–adjusted models were applied to more closely mimic randomization in this study. The reasons that patients discontinued their combination regimens were identified by chart abstraction. Results Full persistence at 1 year was 45% in the MTX ‐ TNF i patients (n = 2,125) and 18% in the triple therapy patients (n = 171) ( P < 0.001). Adherence was higher for the MTX ‐ TNF i group (26%) than the triple therapy group (11%) ( P < 0.0001). The triple therapy group was associated with significantly more treatment discontinuation, which was most often due to adverse drug events from SSZ . Conclusion Differences in persistence and adherence between the MTX ‐ TNF i and triple therapy groups appear to be primarily related to adverse drug events that were most often attributed to SSZ ." @default.
• W2891903398 created "2018-09-27" @default.
• W2891903398 creator A5000754711 @default.
• W2891903398 creator A5037683071 @default.
• W2891903398 creator A5049628665 @default.
• W2891903398 creator A5079338991 @default.
• W2891903398 creator A5086105954 @default.
• W2891903398 creator A5091214306 @default.
• W2891903398 date "2019-08-30" @default.
• W2891903398 modified "2023-10-18" @default.
• W2891903398 title "Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine" @default.
• W2891903398 cites W1963910487 @default.
• W2891903398 cites W1966624777 @default.
• W2891903398 cites W1979251453 @default.
• W2891903398 cites W1987945182 @default.
• W2891903398 cites W1996597661 @default.
• W2891903398 cites W2009187570 @default.
• W2891903398 cites W2019703030 @default.
• W2891903398 cites W2022420916 @default.
• W2891903398 cites W2028764755 @default.
• W2891903398 cites W2075225898 @default.
• W2891903398 cites W2075323628 @default.
• W2891903398 cites W2095898469 @default.
• W2891903398 cites W2100063456 @default.
• W2891903398 cites W2116006532 @default.
• W2891903398 cites W2118063651 @default.
• W2891903398 cites W2126049444 @default.
• W2891903398 cites W2157029647 @default.
• W2891903398 cites W2157510702 @default.
• W2891903398 cites W2159254596 @default.
• W2891903398 cites W2164521956 @default.
• W2891903398 cites W2287906484 @default.
• W2891903398 cites W2312100984 @default.
• W2891903398 cites W2416369278 @default.
• W2891903398 cites W2528767277 @default.
• W2891903398 cites W2605174003 @default.
• W2891903398 cites W2971217817 @default.
• W2891903398 doi "https://doi.org/10.1002/acr.23759" @default.
• W2891903398 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30221485" @default.
• W2891903398 hasPublicationYear "2019" @default.
• W2891903398 type Work @default.
• W2891903398 sameAs 2891903398 @default.
• W2891903398 citedByCount "17" @default.
• W2891903398 countsByYear W28919033982018 @default.
• W2891903398 countsByYear W28919033982019 @default.
• W2891903398 countsByYear W28919033982020 @default.
• W2891903398 countsByYear W28919033982021 @default.
• W2891903398 countsByYear W28919033982022 @default.
• W2891903398 crossrefType "journal-article" @default.
• W2891903398 hasAuthorship W2891903398A5000754711 @default.
• W2891903398 hasAuthorship W2891903398A5037683071 @default.
• W2891903398 hasAuthorship W2891903398A5049628665 @default.
• W2891903398 hasAuthorship W2891903398A5079338991 @default.
• W2891903398 hasAuthorship W2891903398A5086105954 @default.
• W2891903398 hasAuthorship W2891903398A5091214306 @default.
• W2891903398 hasConcept C126322002 @default.
• W2891903398 hasConcept C197934379 @default.
• W2891903398 hasConcept C2776999253 @default.
• W2891903398 hasConcept C2777226972 @default.
• W2891903398 hasConcept C2777575956 @default.
• W2891903398 hasConcept C2778715236 @default.
• W2891903398 hasConcept C2779123688 @default.
• W2891903398 hasConcept C2779134260 @default.
• W2891903398 hasConcept C2779383735 @default.
• W2891903398 hasConcept C2780479503 @default.
• W2891903398 hasConcept C2781059491 @default.
• W2891903398 hasConcept C3008058167 @default.
• W2891903398 hasConcept C524204448 @default.
• W2891903398 hasConcept C71924100 @default.
• W2891903398 hasConcept C90924648 @default.
• W2891903398 hasConceptScore W2891903398C126322002 @default.
• W2891903398 hasConceptScore W2891903398C197934379 @default.
• W2891903398 hasConceptScore W2891903398C2776999253 @default.
• W2891903398 hasConceptScore W2891903398C2777226972 @default.
• W2891903398 hasConceptScore W2891903398C2777575956 @default.
• W2891903398 hasConceptScore W2891903398C2778715236 @default.
• W2891903398 hasConceptScore W2891903398C2779123688 @default.
• W2891903398 hasConceptScore W2891903398C2779134260 @default.
• W2891903398 hasConceptScore W2891903398C2779383735 @default.
• W2891903398 hasConceptScore W2891903398C2780479503 @default.
• W2891903398 hasConceptScore W2891903398C2781059491 @default.
• W2891903398 hasConceptScore W2891903398C3008058167 @default.
• W2891903398 hasConceptScore W2891903398C524204448 @default.
• W2891903398 hasConceptScore W2891903398C71924100 @default.
• W2891903398 hasConceptScore W2891903398C90924648 @default.
• W2891903398 hasFunder F4320306705 @default.
• W2891903398 hasFunder F4320307105 @default.
• W2891903398 hasFunder F4320307115 @default.
• W2891903398 hasFunder F4320307765 @default.
• W2891903398 hasFunder F4320308927 @default.
• W2891903398 hasFunder F4320308971 @default.
• W2891903398 hasFunder F4320309117 @default.
• W2891903398 hasFunder F4320332161 @default.
• W2891903398 hasIssue "10" @default.
• W2891903398 hasLocation W28919033981 @default.
• W2891903398 hasOpenAccess W2891903398 @default.
• W2891903398 hasPrimaryLocation W28919033981 @default.
• W2891903398 hasRelatedWork W148170575 @default.

• next